Review Papers Claim by Claim

Concise critical summary

This multidisciplinary preprint (DOI 10.1101/2025.11.13.688007) reports that Myosin VI (MYO6, MVI) is required for estrogen receptor alpha (ER) nuclear localisation, subnuclear clustering and ER target gene expression in ER positive breast cancer cell models; inhibition or knockdown of MVI (siRNA/CRISPR/TIP chemical probe) disperses ER clusters, reconfigures large scale chromatin contacts, downregulates ER target genes (RNAseq 796 genes altered) and synergises with tamoxifen/fulvestrant, including suppression of constitutively active ER mutants Y537S and D538G (GEO GSE300165 referenced) Primary preprint reporting MVI ER interplay

Detailed review and critique of: Myosin VI orchestrates estrogen-driven gene expression in breast cancer cells

What the paper claims (brief)

• The actin motor Myosin VI (MVI/MYO6) localises to the nucleus in ER positive breast cancer cells and its nuclear pool increases after estradiol stimulation; MVI and ER show strong positive correlation in tumour samples and tissue arrays (Hscore correlation r=0.78) Tissue correlation and expression analysis
• MVI and ER physically and functionally interact: hormone increases MVI/ER subnuclear clustering measured by STORM and Degree of Colocalisation (DoC); perturbing MVI (TIP, siRNA, KO) decreases cluster number/area and ER colocalisation and raises ER diffusion measured by acMFM STORM and single molecule dynamics
• MVI influences large-scale chromatin architecture (Chromosome PAINT for GREB1 chr2 and TFF1 chr21), and MVI ChIP and RNA-seq show MVI occupancy at promoters and broad transcriptional effects (796 genes altered; >80% of downregulated genes contain ERE motifs) Chromatin organisation and transcriptomics
• Functionally, MVI perturbation slows growth, reduces colony formation, impairs migration, and sensitises cells to tamoxifen/fulvestrant; TIP also reduces viability driven by constitutively active ER mutants Y537S/D538G Phenotypic and combination therapy assays

Methods and data sources

Multimodal experimental pipeline: immunofluorescence, nuclear fractionation, STORM SMLM with Clus-DoC cluster and DoC colocalisation analysis (parameters minPts3 epsilon localization precision, cluster min 10 molecules), aberration-corrected multifocal 3D single-molecule tracking (acMFM) with MOSAIC tracking, Chromosome PAINT FISH, ChIP-qPCR, RNA-seq (STAR, Trimmomatic, featureCounts, DESeq2), RT-qPCR, CRISPR KO, siRNA KD, TIP pharmacology (25 muM), endocrine drugs (tamoxifen, fulvestrant), and phenotypic assays. RNAseq deposited in GEO GSE300165 (private until 2026 release) Methods and data deposition

Strengths

• Multidisciplinary approach: high-resolution imaging (STORM), single-molecule tracking (acMFM), chromatin painting, transcriptomics and functional phenotypes increase causal plausibility of MVI role in ER regulation Convergent multimodal evidence
• Clinical relevance supported by expression correlations in TCGA/GTEx and tissue-array Hscore analyses (n=209 tumors) linking MVI to ER positive breast cancer biology Clinical expression correlation
• Therapeutic angle: combination experiments with clinically used endocrine agents and demonstration of effect on common resistance mutants (Y537S/D538G) provide translationally testable predictions Combination therapy and mutant ER suppression

Limitations, caveats and potential biases

1. Reliance on TIP (2,4,6-triiodophenol) as the primary chemical inhibitor. TIP is a small-molecule probe with limited prior in vivo validation; off-target pharmacology is possible and insufficiently excluded here — no kinase profiling or broad off-target panel reported. This weakens causal pharmacology claims unless genetic perturbation fully recapitulates pharmacology (authors use siRNA/KO but further rescue experiments using TIP-resistant MYO6 mutants or orthogonal inhibitors are missing) TIP limitations and specificity concerns
2. Most data are in vitro in cell lines (MCF7, T47D, ZR-75-1, BT-474); while tissue-array correlations are supportive, there is no in vivo tumour model (xenograft or PDX) showing that MVI targeting provides therapeutic benefit and acceptable toxicity; in vivo validation is necessary before translational claims Lack of in vivo validation
3. ChIP evidence: authors present ChIP-qPCR at selected promoters showing MVI occupancy decreased by TIP/starvation, but no genome-wide ChIP-seq or CUT&RUN to define global binding; RNA-seq promoter motif enrichment suggests ER dependence but direct genome-wide promoter co-occupancy by MVI and ER is not shown, leaving mechanistic locus-level claims partially inferred rather than proven Limited ChIP evidence
4. STORM/PAINT resolution versus promoter-level claims: STORM shows clustering at ~20 nm localisation precision and PAINT informs chromosome territory overlaps, but these approaches cannot assign MVI/ER to specific promoter sequences; authors are careful to avoid overclaiming, but readers must not equate cluster colocalisation with promoter binding without locus-resolved biochemical data Imaging resolution caveat
5. GEO RNA-seq accession (GSE300165) is currently private (release scheduled 2026) limiting independent reanalysis for reviewers/readers now; open data would strengthen reproducibility and allow community validation GEO deposition status
6. Population heterogeneity and tissue-array selection bias: arrays include 209 tumours but selection criteria and clinical metadata (ER levels, treatment history, subtype distribution) are not fully presented in the excerpts; this could bias expression correlations and Hscore analyses if arrays are enriched for ER high tumours Tissue array metadata missing

Interpretation: mechanism and plausibility

Biologically, MVI is an unconventional minus-end directed actin motor with known nuclear roles in RNAPII spatial organisation and transcription reported previously; the present data extend that role to a nuclear transporter/scaffolder for ER-driven transcriptional hubs in ER+ breast cancer cells, with functions in cluster assembly, chromatin reorganisation and promoter engagement (supported by ChIP-qPCR and RNA-seq) Mechanistic proposal

What would disprove or weaken the central claim?

• Failure to reproduce the transcriptional and clustering phenotypes using independent, genetically precise perturbations (e.g., complementation of MYO6 KO with WT versus motor-dead or TIP-resistant MYO6) would indicate TIP off-target effects or non-specific KD artefacts Genetic rescue test needed
• If rigorous proteome or kinase off-target profiling shows TIP at 25 muM hits multiple regulators of nuclear transport or chromatin architecture, the pharmacology interpretation would be suspect.
• Lack of effect in in vivo tumour models or primary tumour-derived organoids would reduce translational relevance.

Concrete experiments to strengthen and test the claims (ranked)

1. Genetic rescue series: Express TIP-resistant MYO6 (mutant in TIP binding if known) and motor-dead and cargo-binding mutants in MYO6 KO cells to show phenotypic specificity (restoration of ER clustering and target transcription only by WT rescue) — decisive test of specificity.
2. Genome-wide binding: Perform CUT&RUN or ChIP-seq for MVI and ER ±estrogen ±TIP to map co-occupancy across the genome and directly link MVI occupancy with downregulated ER targets from RNA-seq.
3. Off-target profiling for TIP: run broad kinome and drug-protein panel and transcriptomic signatures to exclude major off-targets at 25 muM; or use at least one orthogonal MVI inhibitor if available.
4. In vivo validation: test TIP or genetic MVI suppression in ER+ xenograft or PDX models alone and combined with endocrine therapy for efficacy and toxicity readouts.
5. Single-locus imaging: Combine DNA-PAINT targeting specific ERE-containing promoters with protein-STORM to demonstrate MVI/ER presence at single promoter loci in intact nuclei.

Paper scoring (critical, evidence-based)

• paper_novelty: 9
• paper_novelty_explanation: The demonstration that an actin motor (MVI) organizes ER nuclear clustering and modulates endocrine resistance mechanisms (including Y537S/D538G) is novel and conceptually expands nuclear motor roles into clinically relevant hormone resistance; few prior studies link MYO6 to hormone receptor transcription hubs at this depth Novel link between MVI and ER-driven resistance
• paper_quality: 9
• paper_quality_explanation: Experiments are technically sophisticated, well-matched, and internally consistent (STORM, acMFM, RNA-seq, ChIP, phenotypes). Methods are described; controls (siRNA, KO) are used; data deposition to GEO present. Main quality caveats are absence of in vivo validation, reliance on a single chemical inhibitor without orthogonal pharmacology/rescue, and private RNA-seq at present delaying community checks.
• paper_generality: 8
• paper_generality_explanation: Findings likely generalize across ER positive breast cancer given tissue data and multiple cell lines, and mechanistic concept (nuclear motors shaping nuclear receptor hubs) may extend to other nuclear receptors, but robustness across tumour heterogeneity and in vivo contexts remains to be shown.
• paper_usefulness: 9
• paper_usefulness_explanation: Identifies MVI as a potential co-target to improve endocrine therapy and to overcome key ER mutations — highly useful for translational research and drug discovery if specificity and safety of inhibitors can be established.
• paper_reproducibility: 8
• paper_reproducibility_explanation: Methods are described with common tools and publicly available software (Clus-DoC, MOSAIC, STAR, DESeq2) and data deposited to GEO; missing open release and some custom code/parameters for image analysis may hamper immediate replication but overall reproducibility is reasonable.
• explanatory_depth: 9
• explanatory_depth_explanation: The paper links molecular dynamics (single-molecule diffusion and clustering) to chromatin architecture and transcriptomics, offering mechanistic depth beyond correlative expression analysis; however, locus-level mechanistic biochemistry (how MVI binds DNA or chromatin-associated proteins to scaffold ER) remains incompletely resolved.

Novel, testable hypotheses generated

1. Hypothesis 1: Nuclear MVI directly stabilises ER at enhancers/promoters via a protein bridge interaction with RNAPII and mediator complex members; loss of MVI increases ER off-rate and decreases enhancer-promoter looping frequency. Test: CUT&RUN for MVI/ER/Pol II and HiChIP for ER-mediated enhancer-promoter contacts ±MVI perturbation.
2. Hypothesis 2: MVI blockade will re-sensitise ER mutant-driven tumours clinically resistant to SERDs/SERMs by disrupting nuclear condensate formation required for mutant ER transcriptional activity. Test: treat PDX models bearing Y537S/D538G with TIP plus fulvestrant compared to controls and measure tumour regression and transcriptomic reversal.

Two concrete experiments (highly specific)

1. Rescue and domain mapping: Create MYO6 KO MCF7 cells and re-express (A) wild type MYO6, (B) motor-dead MYO6 (ATPase-dead), (C) tail-only (cargo-binding deficient), and (D) a TIP-binding site mutant (if mapped). Measure ER clustering by STORM, ER diffusion by acMFM, and ER target gene expression by RT-qPCR. Prediction: only WT rescues clustering and transcription; motor-dead and tail mutants do not; TIP-resistant mutant rescues in the presence of TIP. This directly tests motor activity and binding specificity.
2. Genome-wide co-occupancy and looping: Perform CUT&RUN for MVI and ER and HiChIP for ER-associated interactions in MCF7 ±estradiol ±TIP. Integrate with RNA-seq to identify MVI-dependent ER-bound enhancers/promoters and changes in enhancer-promoter contact frequencies linked to gene expression changes. Prediction: MVI colocalises at a subset of ER enhancers and is necessary for specific enhancer-promoter loops that support high-level ER target gene expression.

For translational development

Before clinical translation, (1) develop orthogonal small-molecule MVI inhibitors or use PROTAC/targeted degradation strategies to validate on-target efficacy; (2) test safety in normal tissues given MVI roles in endocytosis and hearing (MYO6 knockout phenotypes include hearing defects); (3) establish pharmacokinetics and a therapeutic window in vivo; (4) evaluate combination therapy in ER+ PDX models, including those with ESR1 mutations.

Useful resources and data links cited in paper

• Primary preprint and dataset (DOI10.1101/2025.11.13.688007) and GEO deposition GSE300165 (private until 2026) Preprint and GEO deposit
• Clus-DoC software (used for SMLM colocalisation/cluster analysis) repository on GitHub (authors reference this tool in methods) Clus-DoC use in STORM analysis

Interactive visualisations (client-side JS Plotly)

Bottom line (balanced)

The preprint provides substantial, technically rigorous evidence that nuclear Myosin VI contributes to the spatial organisation and transcriptional activity of ER in ER positive breast cancer cell models, and that perturbing MVI reduces ER-target expression and increases sensitivity to endocrine therapy including in common ESR1 mutant contexts; however, important gaps remain (in vivo validation, pharmacological specificity/rescue, genome-wide locus-level occupancy). The work is high-quality and high-impact if orthogonal validation confirms specificity and safety, and it generates clear, testable translational paths.

Suggested next actions for researchers

1. Reproduce key imaging and RNA-seq phenotypes using independent labs and make RNA-seq public for reanalysis.
2. Perform genetic rescue/mutant mapping to confirm on-target TIP mechanism and motor dependence.
3. Assess in vivo efficacy/toxicity in ER+ xenograft and PDX models with ESR1 mutations.